Q2 2026 Merck KGaA Earnings Call Transcript
Key Points
- Merck KGaA (MKGAF) delivered robust Q2 results with organic sales growth accelerating to 4.1%, driven by strong contributions from Life Science and Electronics.
- The company raised its full-year 2026 guidance for organic sales growth, EBITDA pre, and EPS pre, reflecting confidence in continued momentum.
- Life Science showed strong performance, with Process Solutions growing 15% organically, supported by healthy market demand and a successful new go-to-market model.
- Electronics delivered a strong quarter with organic growth accelerating to 11.7%, fueled by 17% growth in Semiconductor Solutions driven by AI-related demand in advanced nodes.
- The planned acquisition of Bio-Techne is on track and expected to be immediately accretive to sales growth and margins, with estimated run-rate cost synergies of approximately EUR140 million by year three.
- Rare Diseases portfolio continues to show strong momentum, with Ogsiveo and Gomekli delivering combined sales of EUR207 million in H1, in line with guidance.
- The company is making progress on its strategic agenda, including opening a new metrology and inspection site in France and advancing its pipeline with FDA breakthrough therapy designation for enpatoran.
- Healthcare organic sales declined by 3.4% in Q2, primarily due to Mavenclad's loss of market exclusivity in the US and continued competition for Bavencio.
- Process Solutions growth is expected to normalize in the second half of 2026, with potential inventory destocking effects possibly impacting 2027 performance.
- Optronics in Electronics remains under pressure from softer demand in consumer electronics, potentially leading to a year-over-year decline in net sales in the second half.
- There is considerable uncertainty regarding the FDA approval of Pergoveris in the US, as the submission is based on legacy data and past discussions with the regulator have been challenging.
- Net financial debt increased to EUR9.2 billion as of June 30, mainly due to dividend payments and financing for the SpringWorks acquisition, with a focus on deleveraging after the Bio-Techne deal closes.
- The company faces headwinds from foreign exchange rates, although these are expected to ease compared to previous guidance.
- Discovery Solutions in Life Science showed only slight growth in a muted market environment, with continued softness in China and academia segments.
Dear ladies and gentlemen, welcome to the Merck investor and analyst conference call on second quarter 2026. (Operator Instructions)
I am now handing over to Florian Schraeder, Head of Investor Relations, who will lead you through this conference. Please go ahead, sir.
Thank you very much, Heidi. Good afternoon, good morning, everyone, and welcome to our Q2 '26 results call. Thank you for joining us today.
My name is Florian Schraeder, and I'm the Head of Investor Relations at Merck. In our Q2 call today, Kai Beckmann, Group CEO, will begin with sharing an update on first steps since we announced our new strategic direction in May. Kai will then provide a brief overview of our business performance and key developments in the second quarter as part of his executive summary. Helene von Roeder, Group CFO, will guide you through the detailed financial overview.
Before we move into the Q&A session where we will be joined by Jean-Charles Wirth, CEO of Life Science; Danny Bar
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
